CA2406745C
(en)
|
2001-11-13 |
2006-01-10 |
The Trustees Of The University Of Pennsylvania |
A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
|
DK1453547T3
(en)
|
2001-12-17 |
2016-12-05 |
Univ Pennsylvania |
ADENOASSOCATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING THESE AND APPLICATIONS THEREOF
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
US9233131B2
(en)
|
2003-06-30 |
2016-01-12 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
AU2004278684B2
(en)
|
2003-09-30 |
2011-05-12 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor
|
WO2006078279A2
(en)
|
2004-04-28 |
2006-07-27 |
The Trustees Of The University Of Pennsylvania |
Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations
|
US9592284B2
(en)
|
2004-04-28 |
2017-03-14 |
The Trustees Of The University Of Pennsylvania |
Immunization regimen with E4-deleted adenovirus prime and E1-deleted adenovirus boost
|
CN112029737A
(zh)
|
2005-04-07 |
2020-12-04 |
宾夕法尼亚大学托管会 |
增强腺相关病毒载体功能的方法
|
WO2007120542A2
(en)
|
2006-03-30 |
2007-10-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Aav capsid library and aav capsid proteins
|
BRPI0710671B8
(pt)
|
2006-04-07 |
2021-05-25 |
Univ Texas |
uso de um vetor de bacteriofágo viral adenoassociado (aavp) terapêutico para a fabricação de um medicamento para o tratamento e profilaxia de uma doença hiperproliferativa
|
CN101495624A
(zh)
*
|
2006-04-28 |
2009-07-29 |
宾夕法尼亚州立大学托管会 |
衣壳免疫原性降低的经修饰aav载体及其用途
|
WO2007127264A2
(en)
|
2006-04-28 |
2007-11-08 |
The Trustees Of The University Of Pennsylvania |
Scalable production method for aav
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
DK2191001T3
(en)
|
2007-04-09 |
2016-09-19 |
Univ Florida |
RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF
|
EP2019143A1
(en)
*
|
2007-07-23 |
2009-01-28 |
Genethon |
CNS gene delivery using peripheral administration of AAV vectors
|
EP2058401A1
(en)
*
|
2007-10-05 |
2009-05-13 |
Genethon |
Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
|
US20090215879A1
(en)
*
|
2008-02-26 |
2009-08-27 |
University Of North Carolina At Chapel Hill |
Methods and compositions for adeno-associated virus (aav) with hi loop mutations
|
US8632764B2
(en)
|
2008-04-30 |
2014-01-21 |
University Of North Carolina At Chapel Hill |
Directed evolution and in vivo panning of virus vectors
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
US8889641B2
(en)
|
2009-02-11 |
2014-11-18 |
The University Of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
EP2425000B1
(en)
*
|
2009-04-30 |
2019-02-20 |
The Trustees Of The University Of Pennsylvania |
Compositions for targeting conducting airway cells comprising adeno-associated virus constructs
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
US9133479B2
(en)
*
|
2009-06-03 |
2015-09-15 |
Cedars-Sinai Medical Center |
Effective vector platform for gene transfer and gene therapy
|
US20120244127A1
(en)
|
2009-10-01 |
2012-09-27 |
The Trustees Of The University Of Pennsylvania |
AAV Vectors Expressing SEC10 for Treating Kidney Damage
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
CN102869779A
(zh)
|
2010-03-29 |
2013-01-09 |
宾夕法尼亚大学托管会 |
药理学诱导的转基因消融系统
|
EP3444346B1
(en)
|
2010-04-23 |
2022-07-27 |
University of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
CA3050894C
(en)
|
2010-04-23 |
2022-10-18 |
University Of Massachusetts |
Multicistronic expression constructs
|
CA3066596A1
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
EP2634253B1
(en)
|
2010-10-27 |
2016-05-11 |
Jichi Medical University |
Adeno-associated virus virions for transferring genes into neural cells
|
WO2012109570A1
(en)
|
2011-02-10 |
2012-08-16 |
The University Of North Carolina At Chapel Hill |
Viral vectors with modified transduction profiles and methods of making and using the same
|
WO2012112832A1
(en)
*
|
2011-02-17 |
2012-08-23 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
|
EP2699688A1
(en)
|
2011-04-20 |
2014-02-26 |
The Trustees Of The University Of Pennsylvania |
Regimens and compositions for aav-mediated passive immunization of airborne pathogens
|
EP3318634A1
(en)
|
2011-04-21 |
2018-05-09 |
University of Massachusetts |
Raav-based compositions and methods for treating diseases involving dominant-negative or gain of function mutations
|
SG10201800873WA
(en)
|
2011-04-22 |
2018-03-28 |
Univ California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
US20130039888A1
(en)
*
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
WO2013029030A1
(en)
|
2011-08-24 |
2013-02-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
New aav capsid proteins for nucleic acid transfer
|
EP2764119A2
(en)
|
2011-10-05 |
2014-08-13 |
Genelux Corporation |
Method for detecting replication or colonization of a biological therapeutic
|
US9226936B2
(en)
|
2011-10-28 |
2016-01-05 |
The Wistar of Anatomy and Biology |
Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells
|
US10238755B2
(en)
|
2011-11-30 |
2019-03-26 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for regulation of cell aging, carcinogenesis and reprogramming
|
EP2601968A1
(en)
*
|
2011-12-06 |
2013-06-12 |
Deutsches Krebsforschungszentrum |
HPV derived polynucleic acids for therapy
|
WO2013103896A1
(en)
|
2012-01-06 |
2013-07-11 |
Mayo Foundation For Medical Education And Research |
Treating cardiovascular or renal diseases
|
WO2013138522A2
(en)
|
2012-03-16 |
2013-09-19 |
Genelux Corporation |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
US20130280170A1
(en)
|
2012-04-20 |
2013-10-24 |
Aladar A. Szalay |
Imaging methods for oncolytic virus therapy
|
JP6385920B2
(ja)
|
2012-05-09 |
2018-09-05 |
オレゴン ヘルス アンド サイエンス ユニバーシティー |
アデノ随伴ウイルスプラスミド及びベクター
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
AU2013287281B2
(en)
|
2012-07-11 |
2018-04-26 |
The Trustees Of The University Of Pennsylvania |
AAV-mediated gene therapy for RPGR x-linked retinal degeneration
|
DK2879719T3
(en)
|
2012-08-01 |
2018-09-03 |
Nationwide Childrens Hospital |
INTRATEKAL ADMINISTRATION OF RECOMBINANT ADENOASSOCATED VIRUSES
|
EP2692868A1
(en)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
|
CN104797593B
(zh)
*
|
2012-09-28 |
2020-05-08 |
北卡罗来纳-查佩尔山大学 |
靶向少突胶质细胞的aav载体
|
US20140140959A1
(en)
|
2012-10-05 |
2014-05-22 |
Aladar A. Szalay |
Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
|
EP2749569A1
(en)
|
2012-12-28 |
2014-07-02 |
Annibale Alessandro Puca |
Variant of BPIFB4 protein
|
US8957044B2
(en)
|
2013-03-01 |
2015-02-17 |
Wake Forest University Health Sciences |
Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
|
AU2014244167A1
(en)
*
|
2013-03-13 |
2015-10-08 |
The Children's Hospital Of Philadelphia |
Adeno-associated virus vectors and methods of use thereof
|
CA2904960A1
(en)
|
2013-03-14 |
2014-10-02 |
University Of Florida Research Foundation, Inc. |
Di-amino acid repeat-containing proteins associated with als
|
PT2984166T
(pt)
|
2013-03-15 |
2020-07-16 |
Univ Pennsylvania |
Composições para tratar mps i
|
WO2014144229A1
(en)
*
|
2013-03-15 |
2014-09-18 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for dual glycan binding aav vectors
|
WO2015012924A2
(en)
|
2013-04-29 |
2015-01-29 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
|
JP6600624B2
(ja)
|
2013-05-31 |
2019-10-30 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
アデノ随伴ウイルス変異体及びその使用方法
|
EP3564379A1
(en)
|
2013-09-13 |
2019-11-06 |
California Institute of Technology |
Selective recovery
|
US20160369298A1
(en)
|
2013-09-26 |
2016-12-22 |
University Of Florida Research Foundation, Inc. |
Synthetic combinatorial aav capsid library for targeted gene therapy
|
WO2015054258A1
(en)
*
|
2013-10-07 |
2015-04-16 |
Kiromic, Llc |
Compositions and methods for treating cardiovascular diseases using disease-specific promoter
|
CN115093464A
(zh)
*
|
2013-10-11 |
2022-09-23 |
马萨诸塞眼科耳科诊所 |
预测祖先病毒序列的方法及其用途
|
WO2015103438A2
(en)
|
2014-01-02 |
2015-07-09 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
GB201403684D0
(en)
*
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
EP3116900B1
(en)
|
2014-03-09 |
2020-07-08 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency
|
WO2015137802A1
(en)
|
2014-03-10 |
2015-09-17 |
Uniqure Ip B.V. |
Further improved aav vectors produced in insect cells
|
EP3119798B1
(en)
|
2014-03-17 |
2020-08-05 |
Adverum Biotechnologies, Inc. |
Compositions and methods for enhanced gene expression in cone cells
|
CA2942515A1
(en)
|
2014-03-18 |
2015-09-24 |
University Of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
EP2933335A1
(en)
|
2014-04-18 |
2015-10-21 |
Genethon |
A method of treating peripheral neuropathies and motor neuron diseases
|
EP3134522B1
(en)
|
2014-04-25 |
2021-10-06 |
University of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
US10780182B2
(en)
|
2014-04-25 |
2020-09-22 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
ES2876409T3
(es)
|
2014-04-25 |
2021-11-12 |
Univ Pennsylvania |
Variantes del RLBD y su uso en composiciones para reducir los niveles de colesterol
|
DK3142750T3
(da)
|
2014-05-13 |
2020-09-14 |
Univ Pennsylvania |
Sammensætninger omfattende aav, som udtrykker dobbelt-antistofkonstrukter og anvendelser deraf
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
EP2960336A1
(en)
|
2014-06-27 |
2015-12-30 |
Genethon |
Efficient systemic treatment of dystrophic muscle pathologies
|
EP3198018B1
(en)
|
2014-09-24 |
2020-12-09 |
City of Hope |
Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
|
EP3795580A1
(en)
|
2014-10-03 |
2021-03-24 |
University of Massachusetts |
High efficiency library-identified aav vectors
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
PL3207130T3
(pl)
|
2014-10-14 |
2020-02-28 |
Halozyme, Inc. |
Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
|
CN107073051B
(zh)
|
2014-10-21 |
2021-08-24 |
马萨诸塞大学 |
重组aav变体及其用途
|
EP3215602B1
(en)
*
|
2014-11-05 |
2019-12-25 |
The Research Institute at Nationwide Children's Hospital |
Methods and materials for producing recombinant viruses in eukaryotic microalgae
|
WO2016073693A2
(en)
|
2014-11-05 |
2016-05-12 |
Voyager Therapeutics, Inc. |
Aadc polynucleotides for the treatment of parkinson's disease
|
SG11201703419UA
(en)
|
2014-11-14 |
2017-05-30 |
Voyager Therapeutics Inc |
Modulatory polynucleotides
|
US10597660B2
(en)
|
2014-11-14 |
2020-03-24 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
JP2017536116A
(ja)
*
|
2014-11-21 |
2017-12-07 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
中枢神経系を標的化したaavベクター
|
WO2016094783A1
(en)
|
2014-12-12 |
2016-06-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
CA2967468A1
(en)
|
2014-12-16 |
2016-06-23 |
Board Of Regents Of The University Of Nebraska |
Gene therapy for juvenile batten disease
|
EP3242945B1
(en)
|
2015-01-07 |
2021-09-01 |
Universitat Autònoma de Barcelona |
Single-vector gene construct comprising insulin and glucokinase genes
|
WO2016115543A2
(en)
|
2015-01-16 |
2016-07-21 |
University Of Washington |
Novel micro-dystrophins and related methods of use
|
US20180030096A1
(en)
|
2015-02-03 |
2018-02-01 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
WO2016130600A2
(en)
|
2015-02-09 |
2016-08-18 |
Duke University |
Compositions and methods for epigenome editing
|
US10584321B2
(en)
|
2015-02-13 |
2020-03-10 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
WO2016141078A1
(en)
|
2015-03-02 |
2016-09-09 |
Avalanche Biotechnologies, Inc. |
Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
|
HUE052577T2
(hu)
|
2015-03-10 |
2021-05-28 |
Univ Columbia |
Rekombináns GLUT1 adeno-asszociált vírusvektor-szerkezetek és kapcsolódó eljárások GLUT1 expresszió helyreállítására
|
US10883117B2
(en)
|
2015-03-24 |
2021-01-05 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
EP3285780A4
(en)
|
2015-04-24 |
2018-12-19 |
University of Massachusetts |
Modified aav constructions and uses thereof
|
EP3288594B1
(en)
|
2015-04-27 |
2022-06-29 |
The Trustees of The University of Pennsylvania |
Dual aav vector system for crispr/cas9 mediated correction of human disease
|
WO2016179496A1
(en)
|
2015-05-07 |
2016-11-10 |
Massachusetts Eye And Ear Infirmary |
Methods of delivering an agent to the eye
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
WO2016183297A1
(en)
|
2015-05-12 |
2016-11-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Aav isolate and fusion protein comprising nerve growth factor signal peptide and parathyroid hormone
|
EP3307310A2
(en)
|
2015-05-13 |
2018-04-18 |
The Trustees Of The University Of Pennsylvania |
Aav-mediated expression of anti-influenza antibodies and methods of use thereof
|
US20170067028A1
(en)
*
|
2015-05-15 |
2017-03-09 |
Douglas J. Ballon |
Radiolabeling of adeno associated virus
|
US10509045B2
(en)
|
2015-05-29 |
2019-12-17 |
University Of Florida Research Foundation, Incorporated |
Methods for diagnosing Huntington's disease
|
WO2017015637A1
(en)
|
2015-07-22 |
2017-01-26 |
Duke University |
High-throughput screening of regulatory element function with epigenome editing technologies
|
ES2945427T3
(es)
*
|
2015-07-30 |
2023-07-03 |
Massachusetts Eye & Ear Infirmary |
Secuencias de AAV ancestrales y usos de las mismas
|
CA2993431A1
(en)
|
2015-07-31 |
2017-02-09 |
Regents Of The University Of Minnesota |
Nuclease based knockouts of immunological checkpoint genes in immune cells
|
WO2017024198A1
(en)
|
2015-08-06 |
2017-02-09 |
The Trustees Of The University Of Pennsylvania |
Glp-1 and use thereof in compositions for treating metabolic diseases
|
MX2018002339A
(es)
|
2015-08-25 |
2018-12-19 |
Univ Duke |
Composiciones y metodos de mejora de la especificidad en ingenieria genomica usando endonucleasas guiadas por arn.
|
US11117942B2
(en)
|
2015-08-31 |
2021-09-14 |
The Trustees Of The University Of Pennsylvania |
AAV-EPO for treating companion animals
|
JP7261583B2
(ja)
|
2015-09-24 |
2023-04-20 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
補体媒介性疾患を処置するための組成物及び方法
|
EP3831842A1
(en)
|
2015-09-28 |
2021-06-09 |
The University of North Carolina at Chapel Hill |
Methods and compositions for antibody-evading virus vectors
|
US11273227B2
(en)
|
2015-10-09 |
2022-03-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treating Stargardt's disease and other ocular disorders
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
WO2017066764A2
(en)
*
|
2015-10-16 |
2017-04-20 |
William Marsh Rice University |
Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
|
US11426469B2
(en)
|
2015-10-22 |
2022-08-30 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
WO2017070476A2
(en)
*
|
2015-10-22 |
2017-04-27 |
University Of Florida Research Foundation, Inc. |
Synthetic combinatorial aav3 capsid library
|
WO2017070525A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
WO2017070491A1
(en)
*
|
2015-10-23 |
2017-04-27 |
Applied Genetic Technologies Corporation |
Ophthalmic formulations
|
EP4316512A3
(en)
|
2015-10-28 |
2024-04-24 |
The Trustees of The University of Pennsylvania |
Intrathecal administration of adeno-associated-viral vectors for gene therapy
|
WO2017075335A1
(en)
|
2015-10-28 |
2017-05-04 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
EP3370778A1
(en)
|
2015-11-05 |
2018-09-12 |
Bamboo Therapeutics, Inc. |
Modified friedreich ataxia genes and vectors for gene therapy
|
CA3006569A1
(en)
|
2015-12-02 |
2017-06-08 |
Voyager Therapeutics, Inc. |
Assays for the detection of aav neutralizing antibodies
|
FR3044926B1
(fr)
|
2015-12-09 |
2020-01-31 |
Genethon |
Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
|
US11098286B2
(en)
|
2015-12-11 |
2021-08-24 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV9
|
ES2934848T3
(es)
|
2015-12-11 |
2023-02-27 |
Univ Pennsylvania |
Método de purificación escalable para AAV8
|
CA3007476A1
(en)
|
2015-12-11 |
2017-06-15 |
Massachusetts Eye And Ear Infirmary |
Materials and methods for delivering nucleic acids to cochlear and vestibular cells
|
CA3008142A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
EP3387137B1
(en)
|
2015-12-11 |
2021-02-03 |
California Institute of Technology |
TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs)
|
US11015173B2
(en)
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV1
|
US11028372B2
(en)
|
2015-12-11 |
2021-06-08 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAVRH10
|
WO2017106345A1
(en)
|
2015-12-14 |
2017-06-22 |
The Trustees Of The University Of Pennsylvania |
Composition for treatment of crigler-najjar syndrome
|
WO2017106354A1
(en)
*
|
2015-12-14 |
2017-06-22 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated viral vectors useful in treatment of spinal muscular atropy
|
CN109069668B
(zh)
|
2015-12-14 |
2023-04-18 |
宾夕法尼亚州大学信托人 |
用于眼病的基因疗法
|
US11826433B2
(en)
|
2016-02-02 |
2023-11-28 |
University Of Massachusetts |
Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
|
BR112018015751A2
(pt)
|
2016-02-03 |
2019-02-05 |
Univ Pennsylvania |
terapia gênica para tratamento de mucopolissacaridose tipo i
|
HUE064408T2
(hu)
|
2016-02-05 |
2024-03-28 |
Univ Emory |
Egyszálú vagy önkomplementer adeno-asszociált vírus 9 injekciója cerebrospinális folyadékba
|
CA3012344A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
JP2019515894A
(ja)
|
2016-04-04 |
2019-06-13 |
ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド |
反復関連非atg(ran)翻訳を調節するためのeif3の操作
|
US11207426B2
(en)
|
2016-04-05 |
2021-12-28 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
MX2018012537A
(es)
|
2016-04-15 |
2019-02-25 |
Univ Pennsylvania |
Terapia de genes para tratar hemofilia a.
|
MA44873A
(fr)
|
2016-04-15 |
2019-03-13 |
Univ Pennsylvania |
Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative
|
MA43552A
(fr)
|
2016-04-15 |
2018-11-07 |
Alpine Immune Sciences Inc |
Protéines immunomodulatrices à variants de cd80 et leurs utilisations
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
BR112018071156A2
(pt)
|
2016-04-15 |
2019-03-12 |
The Trustees Of The University Of Pennsylvania |
terapia de gene para tratar mucopolissacaridose tipo ii
|
JP7140683B2
(ja)
*
|
2016-04-15 |
2022-09-21 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
新規なaav8変異カプシド及びそれを含有する組成物
|
EP3442999A2
(en)
|
2016-04-15 |
2019-02-20 |
Alpine Immune Sciences, Inc. |
Icos ligand variant immunomodulatory proteins and uses thereof
|
US11401527B2
(en)
|
2016-04-17 |
2022-08-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for prophylaxis of organophosphates
|
WO2017189964A2
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
US11326182B2
(en)
|
2016-04-29 |
2022-05-10 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
US10882886B2
(en)
*
|
2016-05-03 |
2021-01-05 |
Children's Medical Research Institute |
Adeno-associated virus polynucleotides, polypeptides and virions
|
ES2941502T3
(es)
|
2016-05-13 |
2023-05-23 |
4D Molecular Therapeutics Inc |
Variantes de cápsides de virus adenoasociado y procedimientos de utilización de las mismas
|
KR20240056729A
(ko)
|
2016-05-18 |
2024-04-30 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
EP3458589A4
(en)
|
2016-05-18 |
2020-01-01 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE
|
WO2017218450A1
(en)
|
2016-06-13 |
2017-12-21 |
The University Of North Carolina At Chapel Hill |
Optimized cln1 genes and expression cassettes and their use
|
WO2017218852A1
(en)
|
2016-06-15 |
2017-12-21 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
CA2971303A1
(en)
|
2016-06-21 |
2017-12-21 |
Bamboo Therapeutics, Inc. |
Optimized mini-dystrophin genes and expression cassettes and their use
|
IL264070B2
(en)
|
2016-07-08 |
2023-03-01 |
Univ Pennsylvania |
Methods and preparations for the treatment of disorders and diseases involving rdh12
|
WO2018022511A1
(en)
|
2016-07-25 |
2018-02-01 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
US11584780B2
(en)
|
2016-07-26 |
2023-02-21 |
Biomarin Pharmaceutical Inc. |
Adeno-associated virus capsid proteins
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
CA3032120A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
EP3827812A1
(en)
|
2016-07-29 |
2021-06-02 |
The Regents of the University of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
CN110650673B
(zh)
|
2016-08-30 |
2024-04-09 |
加利福尼亚大学董事会 |
用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
JP2019530463A
(ja)
|
2016-10-13 |
2019-10-24 |
ユニバーシティ オブ マサチューセッツ |
Aavカプシド設計
|
EP3529359B1
(en)
|
2016-10-18 |
2023-12-13 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes for use in therapy
|
US11192925B2
(en)
|
2016-10-19 |
2021-12-07 |
Adverum Biotechnologies, Inc. |
Modified AAV capsids and uses thereof
|
KR20190099194A
(ko)
|
2016-10-20 |
2019-08-26 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
분비가능한 변이체 면역조절 단백질 및 조작된 세포 치료
|
EP3535396A1
(en)
|
2016-11-01 |
2019-09-11 |
Novartis AG |
Methods and compositions for enhancing gene editing
|
ES2931960T3
(es)
|
2016-12-01 |
2023-01-05 |
Inst Nat Sante Rech Med |
Composiciones farmacéuticas para el tratamiento de enfermedades degenerativas retinianas
|
KR20230160411A
(ko)
|
2016-12-30 |
2023-11-23 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
윌슨병을 치료하기 위한 유전자 치료
|
BR112019013576A2
(pt)
|
2016-12-30 |
2020-02-04 |
Univ Pennsylvania |
terapia genica para o tratamento da fenilcetonuria
|
EP3570895A1
(en)
|
2017-01-17 |
2019-11-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of expressing a polynucleotide of interest in the cone photoreceptors
|
WO2018144709A2
(en)
|
2017-02-01 |
2018-08-09 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating citrullenemia
|
CA3052473A1
(en)
|
2017-02-09 |
2018-08-16 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and compositions and methods thereof
|
AU2018220212A1
(en)
|
2017-02-20 |
2019-08-08 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
JP7237843B2
(ja)
|
2017-02-21 |
2023-03-13 |
ユニバーシティー オブ フロリダ リサーチ ファンデーション, インク. |
修飾されたaavキャプシドタンパク質およびその使用
|
US11518991B2
(en)
|
2017-02-24 |
2022-12-06 |
Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin |
Method for re-expression of different hypermethylated genes involved in fibrosis, like hypermethylated RASAL1 and use thereof in treatment of fibrosis as well as kit of parts for re-expression of hypermethylated genes including RASAL1 in a subject
|
SG10201912976WA
(en)
*
|
2017-02-28 |
2020-02-27 |
Univ Pennsylvania |
Adeno-associated virus (aav) clade f vector and uses therefor
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
SG10201913833PA
(en)
*
|
2017-02-28 |
2020-03-30 |
Univ Pennsylvania |
Influenza vaccines based on aav vectors
|
KR20230093072A
(ko)
|
2017-03-01 |
2023-06-26 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
안구 장애에 대한 유전자 치료
|
US11376321B2
(en)
|
2017-03-02 |
2022-07-05 |
Genethon |
Method for removing anti-AAV antibodies from a blood-derived composition
|
EP3596115A1
(en)
|
2017-03-16 |
2020-01-22 |
Alpine Immune Sciences, Inc. |
Pd-l2 variant immunomodulatory proteins and uses thereof
|
BR112019018747A2
(pt)
|
2017-03-16 |
2020-05-05 |
Alpine Immune Sciences Inc |
proteínas imunomoduladoras variantes de cd80 e usos das mesmas
|
FI3596116T3
(fi)
|
2017-03-16 |
2023-11-09 |
Alpine Immune Sciences Inc |
Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä
|
CA3056249A1
(en)
|
2017-03-24 |
2018-09-27 |
Lankenau Institute For Medical Research |
Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas
|
WO2018177244A1
(zh)
|
2017-03-31 |
2018-10-04 |
舒泰神(北京)生物制药股份有限公司 |
shRNA表达框、携带其的多核苷酸序列及其应用
|
WO2018189208A1
(en)
|
2017-04-10 |
2018-10-18 |
Genethon |
Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies
|
BR112019021569A2
(pt)
|
2017-04-14 |
2020-05-12 |
Regenxbio Inc. |
Precursor de iduronato-2-sulfatase humana recombinante glicosilada (ids), método para tratar um sujeito humano diagnosticado com mucopolissacaridose tipo ii (mps ii)
|
JP2020516674A
(ja)
*
|
2017-04-17 |
2020-06-11 |
ユニバーシティー オブ フロリダ リサーチ ファンデーション, インク. |
PKRおよびeIF2A−P経路によるRANタンパク質翻訳の調節
|
US11879133B2
(en)
|
2017-04-24 |
2024-01-23 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
JP2020518259A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. |
ハンチントン病治療組成物および方法
|
US11603542B2
(en)
|
2017-05-05 |
2023-03-14 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
AU2018264996A1
(en)
|
2017-05-09 |
2019-12-05 |
University Of Massachusetts |
Methods of treating Amyotrophic Lateral Sclerosis (ALS)
|
WO2018209154A1
(en)
*
|
2017-05-10 |
2018-11-15 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modifying assembly-activating protein (app)-dependence of viruses
|
KR20200023280A
(ko)
|
2017-05-11 |
2020-03-04 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
신경 세로이드 지질갈색소증에 대한 유전자 요법
|
WO2018218359A1
(en)
|
2017-05-31 |
2018-12-06 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating peroxisomal disorders
|
WO2018232149A1
(en)
|
2017-06-14 |
2018-12-20 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
EP3676385A1
(en)
|
2017-07-06 |
2020-07-08 |
The Trustees of The University of Pennsylvania |
Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
|
CA3069045A1
(en)
|
2017-07-07 |
2019-01-10 |
Genethon |
Novel polynucleotides encoding a human fkrp protein
|
EP3654860A1
(en)
|
2017-07-17 |
2020-05-27 |
Voyager Therapeutics, Inc. |
Trajectory array guide system
|
KR20200032722A
(ko)
|
2017-07-27 |
2020-03-26 |
노파르티스 아게 |
부분절단효소 내성 trem2 변이체
|
US11512327B2
(en)
|
2017-08-03 |
2022-11-29 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of AAV
|
CN110709511A
(zh)
|
2017-08-28 |
2020-01-17 |
加利福尼亚大学董事会 |
腺相关病毒衣壳变体及其使用方法
|
CR20200165A
(es)
|
2017-09-20 |
2020-06-05 |
4D Molecular Therapeutics Inc |
Variantes de cápsides de virus adenoasociados y métodos de uso de estas
|
EP3684938A1
(en)
|
2017-09-22 |
2020-07-29 |
The Trustees of the University of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
JP7397488B2
(ja)
|
2017-09-22 |
2023-12-13 |
ユニバーシティ オブ マサチューセッツ |
Sod1二重発現ベクターおよびその使用
|
AU2018342105B2
(en)
|
2017-09-26 |
2023-11-16 |
University Of Florida Research Foundation, Incorporated |
Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
AU2018352236A1
(en)
|
2017-10-16 |
2020-04-23 |
The Curators Of The University Of Missouri |
Treatment of amyotrophic lateral sclerosis (ALS)
|
BR112020007405A2
(pt)
|
2017-10-18 |
2020-12-08 |
Regenxbio Inc. |
Produtos terapêuticos de anticorpo pós-translacionalmente modificados totalmente humanos
|
AU2018351000B2
(en)
|
2017-10-18 |
2023-11-30 |
Alpine Immune Sciences, Inc. |
Variant ICOS Ligand immunomodulatory proteins and related compositions and methods
|
CA3079565A1
(en)
|
2017-10-18 |
2019-04-25 |
Regenxbio Inc. |
Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
|
JP7420710B2
(ja)
|
2017-10-20 |
2024-01-23 |
アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) |
組換えaav9由来ベクターの治療有効量の網膜下送達を含む、対象の錐体視細胞において目的のポリヌクレオチドを発現させる方法
|
AU2018372235B9
(en)
|
2017-11-27 |
2022-03-10 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and use for inhibiting angiogenesis
|
WO2019108856A1
(en)
|
2017-11-30 |
2019-06-06 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for mucopolysaccharidosis iiib
|
EP3717653A4
(en)
|
2017-11-30 |
2021-12-01 |
The Trustees of The University of Pennsylvania |
GENE THERAPY FOR MUCOPOLYSACCHARIDOSIS TYPE IIIA
|
EP3727468A4
(en)
|
2017-12-19 |
2021-09-22 |
Akouos, Inc. |
AAV-MEDIATED DELIVERY OF THERAPEUTIC ANTIBODIES TO THE INNER EAR
|
CN111601620A
(zh)
|
2018-01-17 |
2020-08-28 |
阿瑞纳斯治疗公司 |
用于21-羟化酶缺乏症的腺相关病毒基因疗法
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
US11306329B2
(en)
|
2018-02-19 |
2022-04-19 |
City Of Hope |
Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
|
CA3091806A1
(en)
*
|
2018-02-27 |
2019-09-06 |
The Trustees Of The University Of Pennsylvania |
Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
|
EP3768695A4
(en)
*
|
2018-02-27 |
2022-04-06 |
The Trustees of the University of Pennsylvania |
NOVEL ADENO-ASSOCIATED VIRUS (AAV) VECTORS, AAV VECTORS WITH REDUCED CAPSIID DEAMIDATION AND USES THEREOF
|
KR20200131843A
(ko)
*
|
2018-03-16 |
2020-11-24 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
캡시드 변형에 의한 증가하는 조직 특정 유전자 전달
|
EP3774854A1
(en)
|
2018-04-03 |
2021-02-17 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
AU2019249890A1
(en)
|
2018-04-05 |
2020-09-24 |
Association Institut De Myologie |
Hybrid recombinant adeno-associated virus serotype between AAV9 and AAVrh74 with reduced liver tropism
|
US20210231560A1
(en)
|
2018-04-29 |
2021-07-29 |
Regenxbio Inc. |
Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
|
WO2019212921A1
(en)
|
2018-04-29 |
2019-11-07 |
Regenxbio Inc. |
Scalable clarification process for recombinant aav production
|
WO2019217582A1
(en)
|
2018-05-08 |
2019-11-14 |
Rutgers, The State University Of New Jersey |
Aav-compatible laminin-linker polymerization proteins
|
KR20210008501A
(ko)
|
2018-05-09 |
2021-01-22 |
바이오마린 파머수티컬 인크. |
페닐케톤뇨증을 치료하는 방법
|
JP7438981B2
(ja)
|
2018-05-11 |
2024-02-27 |
マサチューセッツ アイ アンド イヤー インファーマリー |
アデノ随伴ウイルスの肝臓特異的向性
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
JP2021523914A
(ja)
|
2018-05-15 |
2021-09-09 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. |
パーキンソン病を治療するための組成物および方法
|
TW202015742A
(zh)
|
2018-05-15 |
2020-05-01 |
美商航海家醫療公司 |
投遞腺相關病毒(aav)之組成物和方法
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
CN112533621A
(zh)
|
2018-06-04 |
2021-03-19 |
卡利迪生物治疗有限公司 |
强化病毒疗法的基于细胞的媒介
|
US11505782B2
(en)
|
2018-06-04 |
2022-11-22 |
Calidi Biotherapeutics, Inc. |
Cell-based vehicles for potentiation of viral therapy
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
US20210301305A1
(en)
|
2018-06-13 |
2021-09-30 |
Voyager Therapeutics, Inc. |
Engineered untranslated regions (utr) for aav production
|
EP3807405A2
(en)
|
2018-06-14 |
2021-04-21 |
REGENXBIO Inc. |
Anion exchange chromatography for recombinant aav production
|
US20210363219A1
(en)
|
2018-06-15 |
2021-11-25 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
WO2020018691A1
(en)
*
|
2018-07-18 |
2020-01-23 |
The General Hospital Corporation |
Modified t cells and methods of their use
|
WO2020023612A1
(en)
|
2018-07-24 |
2020-01-30 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
WO2020028751A2
(en)
|
2018-08-03 |
2020-02-06 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
JP2021533757A
(ja)
|
2018-08-10 |
2021-12-09 |
リジェネクスバイオ インコーポレイテッド |
組換えaav生成のためのスケーラブルな方法
|
US11242528B2
(en)
|
2018-08-28 |
2022-02-08 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
SG11202102058UA
(en)
|
2018-08-30 |
2021-03-30 |
Tenaya Therapeutics Inc |
Cardiac cell reprogramming with myocardin and ascl1
|
CN113966399A
(zh)
|
2018-09-26 |
2022-01-21 |
加州理工学院 |
用于靶向基因疗法的腺相关病毒组合物
|
SG11202103151RA
(en)
|
2018-09-28 |
2021-04-29 |
Voyager Therapeutics Inc |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
CN112752583A
(zh)
|
2018-10-01 |
2021-05-04 |
宫崎彻 |
神经变性疾病治疗剂
|
AU2019351815A1
(en)
|
2018-10-01 |
2021-05-06 |
The Trustees Of The University Of Pennsylvania |
Compositions useful for treating GM1 gangliosidosis
|
US20210348242A1
(en)
|
2018-10-04 |
2021-11-11 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
TW202028458A
(zh)
*
|
2018-10-05 |
2020-08-01 |
美商航海家醫療公司 |
編碼腺相關病毒(aav)生產蛋白之經基因工程化核酸構築體
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
AU2019362833A1
(en)
|
2018-10-15 |
2021-04-29 |
Regenxbio Inc. |
Method for measuring the infectivity of replication defective viral vectors and viruses
|
TW202028468A
(zh)
|
2018-10-15 |
2020-08-01 |
美商航海家醫療公司 |
用於桿狀病毒/Sf9系統中rAAV之大規模生產的表現載體
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
MX2021004602A
(es)
|
2018-10-22 |
2021-09-08 |
Univ Rochester |
Edición del genoma por inserción no homóloga de adn dirigida utilizando una proteína de fusión retroviral integrasacas9.
|
WO2020086742A1
(en)
|
2018-10-24 |
2020-04-30 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
EP3876951A1
(en)
|
2018-11-06 |
2021-09-15 |
Calidi Biotherapeutics, Inc. |
Enhanced systems for cell-mediated oncolytic viral therapy
|
JP7069426B2
(ja)
|
2018-11-16 |
2022-05-17 |
アステラス製薬株式会社 |
ユートロフィン遺伝子を標的とした筋ジストロフィーの治療方法
|
EP3884041A2
(en)
|
2018-11-21 |
2021-09-29 |
Indapta Therapeutics, Inc. |
Methods for expansion of natural killer (nk) cell subset and related compositions and methods
|
US20220372106A1
(en)
|
2018-11-30 |
2022-11-24 |
Alpine Immune Sciences, Inc. |
Cd86 variant immunomodulatory proteins and uses thereof
|
WO2020140007A1
(en)
|
2018-12-28 |
2020-07-02 |
University Of Rochester |
Gene therapy for best1 dominant mutations
|
ES2970216T3
(es)
|
2019-01-04 |
2024-05-27 |
Ultragenyx Pharmaceutical Inc |
Constructos de terapia génica para tratar la enfermedad de Wilson
|
US20220090088A1
(en)
|
2019-01-14 |
2022-03-24 |
University Of Rochester |
Targeted Nuclear RNA Cleavage and Polyadenylation with CRISPR-Cas
|
TW202039858A
(zh)
|
2019-01-18 |
2020-11-01 |
美商航海家醫療公司 |
用於生產aav顆粒之方法及系統
|
EP3917566A4
(en)
|
2019-01-31 |
2022-10-26 |
Oregon Health & Science University |
METHODS OF USING DIRECTED, TRANSCRIPTION-DEPENDENT EVOLUTION OF AAV CAPSIDS
|
SG11202108504YA
(en)
|
2019-02-22 |
2021-09-29 |
Univ Pennsylvania |
Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
|
AU2020229085A1
(en)
|
2019-02-25 |
2021-08-19 |
Friedrich Miescher Institute For Biomedical Research |
Compositions and methods to treat bietti crystalline dystrophy
|
CN113474461A
(zh)
|
2019-02-25 |
2021-10-01 |
诺华股份有限公司 |
治疗bietti晶体营养不良的组合物和方法
|
TW202045728A
(zh)
|
2019-02-26 |
2020-12-16 |
賓州大學委員會 |
用於治療克拉培氏病之組成物
|
WO2020176809A1
(en)
|
2019-02-27 |
2020-09-03 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
TW202102525A
(zh)
|
2019-03-21 |
2021-01-16 |
美商史崔德生物公司 |
重組腺相關病毒載體
|
US20220204574A1
(en)
|
2019-03-25 |
2022-06-30 |
Genethon |
Production of large-sized quasidystrophins using overlapping aav vectors
|
KR20220004987A
(ko)
|
2019-04-03 |
2022-01-12 |
리젠엑스바이오 인크. |
눈 병리에 대한 유전자 요법
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
WO2020210600A1
(en)
|
2019-04-11 |
2020-10-15 |
Regenxbio Inc. |
Methods of size exclusion chromatography for the characterization of recombinant adeno-associated virus compositions
|
MX2021012564A
(es)
|
2019-04-19 |
2022-01-18 |
Regenxbio Inc |
Formulaciones y métodos de vectores de virus adenoasociados.
|
CN114144197A
(zh)
|
2019-04-24 |
2022-03-04 |
再生生物股份有限公司 |
完全人类翻译后修饰的抗体治疗剂
|
CA3134507A1
(en)
*
|
2019-04-29 |
2020-11-05 |
Kalyani NAMBIAR |
Novel aav capsids and compositions containing same
|
WO2020223274A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
|
WO2020223280A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
EP3966227A1
(en)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
AR118928A1
(es)
|
2019-05-14 |
2021-11-10 |
Biomarin Pharm Inc |
Métodos de redosificación de vectores de terapia génica
|
BR112021023899A2
(pt)
|
2019-05-28 |
2022-01-18 |
Astellas Pharma Inc |
Método para o tratamento da distrofia muscular por direcionamento ao gene da dmpk
|
CN114207120A
(zh)
|
2019-05-30 |
2022-03-18 |
坚固生物科技公司 |
重组疱疹病毒载体
|
CA3144864A1
(en)
|
2019-06-27 |
2020-12-30 |
Pfizer Inc. |
Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
|
CN114616000A
(zh)
|
2019-07-02 |
2022-06-10 |
M6P医疗(瑞士)有限责任公司 |
载体组合物及其用于治疗溶酶体贮积症的方法
|
WO2021005223A1
(en)
|
2019-07-10 |
2021-01-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of epilepsy
|
US20230137971A1
(en)
|
2019-07-11 |
2023-05-04 |
Tenaya Therapeutics Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
ES2964907T3
(es)
|
2019-07-11 |
2024-04-10 |
Centre Nat Rech Scient |
Virus adenoasociado modificado químicamente
|
US10801042B1
(en)
|
2019-07-15 |
2020-10-13 |
Vigene Biosciences, Inc. |
Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
|
US10653731B1
(en)
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
US10557149B1
(en)
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
JP2022544015A
(ja)
|
2019-07-23 |
2022-10-17 |
ユニバーシティ オブ ロチェスター |
CRISPR-Casでの標的化されたRNA切断
|
US20230042103A1
(en)
|
2019-07-26 |
2023-02-09 |
Regenxbio Inc. |
Engineered nucleic acid regulatory element and methods of uses thereof
|
EP4007814A1
(en)
|
2019-07-26 |
2022-06-08 |
Akouos, Inc. |
Methods of treating hearing loss using a secreted target protein
|
WO2021030125A1
(en)
|
2019-08-09 |
2021-02-18 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
CA3146751A1
(en)
|
2019-08-16 |
2021-02-25 |
Yuanbo QIN |
Method for treating muscular dystrophy by targeting lama1 gene
|
US20220288235A1
(en)
*
|
2019-08-20 |
2022-09-15 |
St. Jude Children's Research Hospital, Inc. |
SCHIZOPHRENIA-RELATED MICRODELETION GENE 2510002D24Rik IS ESSENTIAL FOR SOCIAL MEMORY
|
TW202122419A
(zh)
|
2019-08-26 |
2021-06-16 |
美商銳進科斯生物股份有限公司 |
以全人類轉譯後修飾之抗VEGF Fab治療糖尿病性視網膜病變
|
WO2021040736A1
(en)
|
2019-08-30 |
2021-03-04 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
US20220333133A1
(en)
|
2019-09-03 |
2022-10-20 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
US20220348937A1
(en)
|
2019-09-06 |
2022-11-03 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
KR20220079857A
(ko)
|
2019-09-13 |
2022-06-14 |
루트거스, 더 스테이트 유니버시티 오브 뉴 저지 |
Aav-상용성 라미닌-링커 중합 단백질
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
JP2022549098A
(ja)
|
2019-09-19 |
2022-11-24 |
ジェネトン |
Fkrpの心毒性を軽減する遺伝子治療発現系
|
US20220347298A1
(en)
|
2019-10-04 |
2022-11-03 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
MX2022004146A
(es)
|
2019-10-07 |
2022-09-19 |
Regenxbio Inc |
Composición farmacéutica de vector de virus adenoasociado y métodos.
|
CN114761546A
(zh)
|
2019-10-08 |
2022-07-15 |
波士顿学院董事会 |
含有多个不同非天然氨基酸的蛋白质以及制备和使用此类蛋白质的方法
|
US20220362402A1
(en)
|
2019-10-08 |
2022-11-17 |
Exhaura, Ltd. |
Compositions and methods for ocular therapy
|
MX2022004352A
(es)
|
2019-10-17 |
2022-07-19 |
Stridebio Inc |
Vectores virales adenoasociados para el tratamiento de la enfermedad de niemann-pick tipo c.
|
US20220396808A1
(en)
*
|
2019-11-08 |
2022-12-15 |
President And Fellows Of Harvard College |
Viral capsid polypeptides
|
EP4055034A4
(en)
*
|
2019-11-08 |
2024-05-29 |
Harvard College |
VIRAL CAPSID POLYPEPTIDES
|
WO2021099394A1
(en)
|
2019-11-19 |
2021-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antisense oligonucleotides and their use for the treatment of cancer
|
TW202134260A
(zh)
|
2019-11-28 |
2021-09-16 |
美商銳進科斯生物股份有限公司 |
微小肌縮蛋白基因療法之構築體及其用途
|
WO2021116138A1
(en)
|
2019-12-09 |
2021-06-17 |
Ucl Business Ltd |
Gene therapy composition and treatment for myh7-linked cardiomyopathy
|
JP2023505851A
(ja)
|
2019-12-10 |
2023-02-13 |
武田薬品工業株式会社 |
ハンター病治療用のアデノ随伴ウイルスベクター
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
KR20220131522A
(ko)
|
2020-01-22 |
2022-09-28 |
리젠엑스바이오 인크. |
완전-인간 글리코실화된 인간 알파-l-이두로니다아제 (idua)를 사용한 점액다당류증 i의 치료
|
CA3167741A1
(en)
|
2020-01-29 |
2021-08-05 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) produced by human neural or glial cells
|
WO2021154956A1
(en)
|
2020-01-29 |
2021-08-05 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis iva
|
MX2022009462A
(es)
|
2020-02-02 |
2022-11-10 |
Univ Pennsylvania |
Composiciones útiles para tratar la gangliosidosis gm1.
|
CN115335526A
(zh)
|
2020-02-07 |
2022-11-11 |
罗切斯特大学 |
核酶介导的rna组装和表达
|
JP2023513211A
(ja)
|
2020-02-07 |
2023-03-30 |
ユニバーシティ オブ ロチェスター |
タンパク質合成を増強するためのCRISPR-Cas13による標的RNA翻訳
|
KR20220140537A
(ko)
|
2020-02-14 |
2022-10-18 |
울트라제닉스 파마수티컬 인코포레이티드 |
Cdkl5 결핍 장애를 치료하기 위한 유전자 요법
|
JP2023515820A
(ja)
|
2020-02-28 |
2023-04-14 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
メープルシロップ尿症の遺伝子治療
|
JP2023515672A
(ja)
|
2020-03-02 |
2023-04-13 |
テナヤ セラピューティクス, インコーポレイテッド |
心筋細胞発現マイクロrnaによる遺伝子ベクター制御
|
CN115484978A
(zh)
|
2020-03-05 |
2022-12-16 |
尼奥克斯医疗有限公司 |
使用免疫细胞治疗癌症的方法和组合物
|
CN115485289A
(zh)
|
2020-03-11 |
2022-12-16 |
宾夕法尼亚大学董事会 |
使用工程化的病毒颗粒进行基因递送的方法和组合物
|
EP4121544A1
(en)
|
2020-03-19 |
2023-01-25 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
|
JP2023519344A
(ja)
|
2020-03-27 |
2023-05-10 |
ユニバーシティ オブ ロチェスター |
CRISPR-Cas13 crRNAアレイ
|
US20240024520A1
(en)
|
2020-03-27 |
2024-01-25 |
UCB Biopharma SRL |
Autonomous knob domain peptides
|
JP2023519307A
(ja)
|
2020-03-27 |
2023-05-10 |
ユニバーシティ オブ ロチェスター |
Crispr-cas13によるウイルスrnaの標的化破壊
|
US20230129893A1
(en)
|
2020-03-31 |
2023-04-27 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating propionic acidemia
|
US20230131352A1
(en)
|
2020-04-01 |
2023-04-27 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
EP4132955A2
(en)
|
2020-04-10 |
2023-02-15 |
SOLA Biosciences LLC |
Compositions and methods for the treatment of protein aggregation disorders
|
CN116249712A
(zh)
|
2020-04-15 |
2023-06-09 |
沃雅戈治疗公司 |
Tau结合化合物
|
US20230190801A1
(en)
|
2020-04-22 |
2023-06-22 |
Indapta Therapeutics, Inc. |
Natural killer (nk) cell compositions and methods for generating same
|
JP2023524414A
(ja)
|
2020-04-28 |
2023-06-12 |
ソラ・バイオサイエンシズ・エルエルシー |
Tdp-43プロテイノパチーの処置のための組成物および方法
|
WO2021226267A2
(en)
*
|
2020-05-05 |
2021-11-11 |
Duke University |
Cross-species compatible adeno-associated virus compositions and methods of use thereof
|
WO2021231443A1
(en)
|
2020-05-12 |
2021-11-18 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of krabbe disease
|
IL298138A
(en)
|
2020-05-12 |
2023-01-01 |
Univ Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
EP4165194A2
(en)
|
2020-05-13 |
2023-04-19 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
CN116096734A
(zh)
|
2020-05-13 |
2023-05-09 |
沃雅戈治疗公司 |
Aav衣壳的向性的重定向
|
IL298128A
(en)
|
2020-05-13 |
2023-01-01 |
Akouos Inc |
Compositions and methods for treating slc26a4-associated hearing loss
|
WO2021230385A1
(en)
|
2020-05-15 |
2021-11-18 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting utrophin gene
|
WO2021236908A2
(en)
|
2020-05-20 |
2021-11-25 |
Biomarin Pharmaceutical Inc. |
Use of regulatory proteins for the production of adeno-associated virus
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
WO2021248038A1
(en)
|
2020-06-05 |
2021-12-09 |
Sola Biosciences Llc |
Compositions and methods for the treatment of synucleinopathies
|
CA3183153A1
(en)
|
2020-06-17 |
2021-12-23 |
Christian HINDERER |
Compositions and methods for treatment of gene therapy patients
|
CA3182313A1
(en)
|
2020-06-19 |
2021-12-23 |
Isabelle Richard |
Gene therapy expression system allowing an adequate expression in the muscles and in the heart of sgcg
|
MX2023000318A
(es)
*
|
2020-07-07 |
2023-02-09 |
Univ Texas |
Vector de virus adenoasociado para marco de lectura abierto peque?o.
|
WO2022011262A1
(en)
|
2020-07-10 |
2022-01-13 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating epilepsy
|
US20230277686A1
(en)
|
2020-07-10 |
2023-09-07 |
Genethon |
A novel muscle-specific promoter
|
CN116438311A
(zh)
|
2020-07-13 |
2023-07-14 |
宾夕法尼亚州大学信托人 |
可用于治疗夏科-马里-图思病的组合物
|
US20230348871A1
(en)
|
2020-07-15 |
2023-11-02 |
University Of Rochester |
Targeted RNA cleavage with dCas13-RNase Fusion Proteins
|
WO2022026410A2
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
EP4189095A1
(en)
|
2020-07-27 |
2023-06-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
CN111876432B
(zh)
*
|
2020-07-29 |
2022-10-28 |
舒泰神(北京)生物制药股份有限公司 |
一组肝靶向新型腺相关病毒的获得及其应用
|
WO2022032153A1
(en)
|
2020-08-06 |
2022-02-10 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
EP4196494A1
(en)
|
2020-08-17 |
2023-06-21 |
Massachusetts Institute of Technology |
Shank3 gene therapy approaches
|
EP4200429A1
(en)
|
2020-08-24 |
2023-06-28 |
The Trustees of The University of Pennsylvania |
Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
|
KR20230058102A
(ko)
|
2020-08-26 |
2023-05-02 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Grn 관련 성인 발병 신경변성 치료를 위한 재조합 아데노-연관 바이러스
|
WO2022050413A1
(ja)
|
2020-09-04 |
2022-03-10 |
国立大学法人神戸大学 |
小型化シチジンデアミナーゼを含む二本鎖dnaの改変用複合体
|
WO2022060916A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized antibodies for anti-viral therapy
|
WO2022060915A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized lanadelumab and administration thereof
|
US20230383278A1
(en)
|
2020-09-18 |
2023-11-30 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
US20230381341A1
(en)
|
2020-10-07 |
2023-11-30 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
KR20230106598A
(ko)
|
2020-10-07 |
2023-07-13 |
리젠엑스바이오 인크. |
겔 제형과 같은 맥락막위 투여용 제형
|
CA3198368A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as formulations with aggregate formation
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
KR20230083287A
(ko)
|
2020-10-07 |
2023-06-09 |
리젠엑스바이오 인크. |
Cln2 질환의 안구 징후에 대한 유전자 요법
|
EP4225270A1
(en)
|
2020-10-07 |
2023-08-16 |
RegenxBio Inc. |
Formulations for suprachoroidal administration such as high viscosity formulations
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
CA3193833A1
(en)
|
2020-10-09 |
2022-04-14 |
Juliette HORDEAUX |
Compositions and methods for treatment of fabry disease
|
TW202229315A
(zh)
|
2020-10-18 |
2022-08-01 |
賓州大學委員會 |
改良的腺相關病毒(aav)載體及其用途
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
AU2021371307A1
(en)
|
2020-10-28 |
2023-06-01 |
Regenxbio, Inc. |
VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
WO2022094255A2
(en)
|
2020-10-29 |
2022-05-05 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|
IL302282A
(en)
|
2020-10-29 |
2023-06-01 |
Regenxbio Inc |
Vectored TNF-alpha antagonists for ocular indications
|
CA3196778A1
(en)
|
2020-11-02 |
2022-05-05 |
Biomarin Pharmaceutical, Inc. |
Process for enriching adeno-associated virus
|
IL302608A
(en)
|
2020-11-03 |
2023-07-01 |
Pfizer |
Methods for producing AAV vectors using ion exchange chromatography
|
KR20230117157A
(ko)
|
2020-12-01 |
2023-08-07 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
조직 특이적 표적화 모티프를 갖는 신규 조성물 및 이를 포함하는 조성물
|
JP2023551533A
(ja)
|
2020-12-01 |
2023-12-08 |
アコーオス インコーポレイテッド |
前庭神経鞘腫関連症状を治療するための抗vegf抗体構築物及び関連する方法
|
CA3200192A1
(en)
|
2020-12-01 |
2022-06-09 |
Justin PERCIVAL |
Compositions and uses thereof for treatment of angelman syndrome
|
US20240052322A1
(en)
|
2020-12-15 |
2024-02-15 |
Pfizer Inc. |
HILIC UPLC-MS Method For Separating and Analyzing Intact Adeno-Associated Virus Capsid Proteins
|
JP2023554389A
(ja)
|
2020-12-16 |
2023-12-27 |
リジェネクスバイオ インコーポレイテッド |
組換えアデノ随伴ウイルスウイルス粒子を生成する方法
|
US20240043869A1
(en)
|
2020-12-23 |
2024-02-08 |
Pfizer Inc. |
Methods for purification of aav vectors by affinity chromatography
|
WO2022147087A1
(en)
|
2020-12-29 |
2022-07-07 |
Regenxbio Inc. |
Tau-specific antibody gene therapy compositions, methods and uses thereof
|
EP4271419A1
(en)
|
2020-12-29 |
2023-11-08 |
Akouos, Inc. |
Compositions and methods for treating clrn1-associated hearing loss and/or vision loss
|
WO2022147480A1
(en)
|
2020-12-30 |
2022-07-07 |
Ansun Biopharma, Inc. |
Oncolytic virus encoding sialidase and multispecific immune cell engager
|
MX2023008595A
(es)
|
2021-01-21 |
2023-09-14 |
Regenxbio Inc |
Produccion mejorada de polipeptidos y virus recombinantes.
|
EP4281551A1
(en)
*
|
2021-01-25 |
2023-11-29 |
Trames Bio, Inc. |
Adeno-associated virus capsids and engineered ligand-gated ion channels for treating focal epilepsy and neuropathic pain
|
WO2022165313A1
(en)
|
2021-02-01 |
2022-08-04 |
Regenxbio Inc. |
Gene therapy for neuronal ceroid lipofuscinoses
|
EP4288553A1
(en)
*
|
2021-02-02 |
2023-12-13 |
University of Massachusetts |
Inverted terminal repeats from aav serotypes 8 and rh.39 in gene therapy vectors
|
EP4288555A1
(en)
|
2021-02-05 |
2023-12-13 |
Maze Therapeutics, Inc. |
Vectors comprising stuffer polynucleotide sequences
|
CA3210955A1
(en)
*
|
2021-02-09 |
2022-08-18 |
Affinia Therapeutics Inc. |
Recombinant aavs with improved tropism and specificity
|
BR112023016075A2
(pt)
|
2021-02-10 |
2023-11-21 |
Regenxbio Inc |
Método para tratar hepatoesplenomegalia, método de distribuição de um raav que codifica hids, método para tratar um sujeito humano, método de tratamento de um sujeito humano, método para determinar a eficácia do tratamento, método para identificar um sujeito como tendo mps ii
|
US20240175054A1
(en)
|
2021-02-26 |
2024-05-30 |
Takeda Pharmaceutical Company Limited |
Composition and methods for the treatment of fabry disease
|
US20240141377A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
US20240141378A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
JP2024511024A
(ja)
|
2021-03-19 |
2024-03-12 |
アドリーナス セラピューティクス, インコーポレイテッド |
21-ヒドロキシラーゼ欠損症の遺伝子治療
|
WO2022208342A1
(en)
|
2021-04-01 |
2022-10-06 |
Pfizer Inc. |
Pharmaceutical compositions containing adeno-associated viral vector
|
EP4320139A1
(en)
|
2021-04-05 |
2024-02-14 |
Solid Biosciences Inc. |
Recombinant herpesvirales vector
|
KR20230170022A
(ko)
|
2021-04-12 |
2023-12-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
척수 및 연수 근위축증(sbma) 치료에 유용한 조성물
|
AR125406A1
(es)
|
2021-04-23 |
2023-07-12 |
Univ Pennsylvania |
Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen
|
CA3216146A1
(en)
|
2021-04-23 |
2022-10-27 |
Douglas Anderson |
Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas fusion protein and methods of treatment
|
IL307902A
(en)
|
2021-04-26 |
2023-12-01 |
Regenxbio Inc |
Administering microdystrophin gene therapy to treat dystrophinopathy
|
WO2022229807A1
(en)
|
2021-04-26 |
2022-11-03 |
Pfizer Inc. |
Adeno-associated viral vector capsids with improved tissue tropism
|
WO2022235614A2
(en)
|
2021-05-04 |
2022-11-10 |
Regenxbio Inc. |
Novel aav vectors and methods and uses thereof
|
WO2022241030A1
(en)
|
2021-05-11 |
2022-11-17 |
Regenxbio Inc. |
Treatment of duchenne muscular dystrophy and combinations thereof
|
CN117813314A
(zh)
*
|
2021-06-08 |
2024-04-02 |
Nf2治疗公司 |
用于治疗神经纤维瘤疾患的组合物和方法
|
EP4355888A1
(en)
*
|
2021-06-18 |
2024-04-24 |
Dyno Therapeutics, Inc. |
Capsid variants and methods of using the same
|
EP4359547A1
(en)
|
2021-06-22 |
2024-05-01 |
Pfizer Inc. |
Production of adeno-associated virus vector in insect cells
|
WO2022272056A2
(en)
*
|
2021-06-24 |
2022-12-29 |
University Of Utah Research Foundation |
Compositions and methods for treating pgm1 deficiency
|
WO2023278811A1
(en)
|
2021-07-01 |
2023-01-05 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
EP4367251A1
(en)
|
2021-07-08 |
2024-05-15 |
Tenaya Therapeutics, Inc. |
Optimized expression cassettes for gene therapy
|
CA3226452A1
(en)
|
2021-07-19 |
2023-01-26 |
New York University |
Auf1 combination therapies for treatment of muscle degenerative disease
|
EP4359551A2
(en)
*
|
2021-07-23 |
2024-05-01 |
Duke University |
Adeno-associated virus compositions and methods of use thereof
|
EP4378472A1
(en)
|
2021-07-30 |
2024-06-05 |
Toru Miyazaki |
Therapeutic agent for ischemic disease
|
AU2022326565A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
IL310691A
(en)
|
2021-08-11 |
2024-04-01 |
Sana Biotechnology Inc |
Genetically modified primary cells for allogeneic cell therapy
|
WO2023019225A2
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
AU2022325231A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
AR126877A1
(es)
*
|
2021-08-25 |
2023-11-22 |
Canbridge Pharmaceuticals Inc |
PARTÍCULAS DE AAV QUE COMPRENDEN UNA PROTEÍNA DE LA CÁPSIDE HEPATOTRÓPICA Y a-GLUCOSIDASA ÁCIDA (GAA) Y SU USO PARA TRATAR LA ENFERMEDAD DE POMPE
|
TW202330929A
(zh)
*
|
2021-08-25 |
2023-08-01 |
美商北海康成製藥有限公司 |
包含肝向性殼體蛋白質和α-半乳糖苷酶的AAV顆粒及其治療法布立症的用途
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
JP7175044B1
(ja)
|
2021-09-24 |
2022-11-18 |
株式会社中山事務所 |
波力発電装置
|
IL311572A
(en)
|
2021-09-30 |
2024-05-01 |
Akouos Inc |
Compositions and methods for treating KCNQ4-related hearing loss
|
TW202325845A
(zh)
|
2021-10-02 |
2023-07-01 |
賓州大學委員會 |
新穎aav衣殼及含其之組成物
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
WO2023060269A1
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
WO2023060272A2
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
WO2023060221A2
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of proteopathies
|
CA3234720A1
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of p53-mediated cancers
|
AU2022366947A1
(en)
|
2021-10-12 |
2024-05-02 |
Bridgebio Gene Therapy Llc |
Methods and compositions for treating leukodystrophies
|
WO2023069987A1
(en)
|
2021-10-20 |
2023-04-27 |
University Of Rochester |
Rejuvenation treatment of age-related white matter loss cross reference to related application
|
WO2023077092A1
(en)
|
2021-10-28 |
2023-05-04 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
WO2023081633A1
(en)
|
2021-11-02 |
2023-05-11 |
University Of Rochester |
Tcf7l2 mediated remyelination in the brain
|
WO2023081648A1
(en)
|
2021-11-02 |
2023-05-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2023087019A2
(en)
|
2021-11-15 |
2023-05-19 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
TW202334181A
(zh)
|
2021-11-17 |
2023-09-01 |
美商航海家醫療公司 |
Aav蛋白殼變異體及其用途
|
WO2023091949A2
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
WO2023102517A1
(en)
|
2021-12-02 |
2023-06-08 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
WO2023114816A1
(en)
|
2021-12-14 |
2023-06-22 |
Neurogene, Inc. |
Recombinant optimized galc constructs and methods for treating galc-associated disorders
|
US20230323395A1
(en)
*
|
2021-12-15 |
2023-10-12 |
Homology Medicines, Inc. |
Methods and compositions for the production of adeno-associated virus
|
AR128239A1
(es)
|
2022-01-10 |
2024-04-10 |
Univ Pennsylvania |
Composiciones y métodos útiles para el tratamiento de trastornos mediados por c9orf72
|
WO2023133584A1
(en)
|
2022-01-10 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of metachromatic leukodystrophy
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023135316A1
(en)
|
2022-01-17 |
2023-07-20 |
Dinaqor Ag |
Gene therapy composition and treatment for dystrophin-related cardiomyopathy
|
EP4215614A1
(en)
|
2022-01-24 |
2023-07-26 |
Dynacure |
Combination therapy for dystrophin-related diseases
|
WO2023147304A1
(en)
|
2022-01-25 |
2023-08-03 |
The Trustees Of The University Of Pennsylvania |
Aav capsids for improved heart transduction and detargeting of liver
|
WO2023147374A2
(en)
|
2022-01-25 |
2023-08-03 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
GB202201242D0
(en)
|
2022-01-31 |
2022-03-16 |
Univ Edinburgh |
Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023150142A1
(en)
|
2022-02-02 |
2023-08-10 |
Akouos, Inc. |
Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
|
WO2023154693A1
(en)
|
2022-02-08 |
2023-08-17 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
WO2023164545A1
(en)
|
2022-02-23 |
2023-08-31 |
Massachusetts Institute Of Technology |
Methods for upregulating shank3 expression
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
WO2023178053A1
(en)
|
2022-03-13 |
2023-09-21 |
Regenxbio Inc. |
Modified muscle-specific promoters
|
WO2023178220A1
(en)
|
2022-03-16 |
2023-09-21 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
WO2023183623A1
(en)
|
2022-03-25 |
2023-09-28 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
WO2023187728A1
(en)
|
2022-04-01 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
Gene therapy for diseases with cns manifestations
|
WO2023196873A1
(en)
|
2022-04-06 |
2023-10-12 |
Regenxbio Inc. |
Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene forsuprachoidal administration
|
TW202345913A
(zh)
|
2022-04-06 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如凝膠調配物
|
TW202404651A
(zh)
|
2022-04-06 |
2024-02-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如形成聚集體之調配物
|
WO2023196892A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
|
WO2023196893A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating her2 positive metastatic breast cancer and other cancers
|
TW202404993A
(zh)
|
2022-04-11 |
2024-02-01 |
美商特納亞治療股份有限公司 |
具經工程化蛋白殼之腺相關病毒
|
WO2023198652A1
(en)
|
2022-04-11 |
2023-10-19 |
Centre National De La Recherche Scientifique |
Chemically-modified adeno-associated viruses
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
WO2023201308A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
WO2023205610A2
(en)
|
2022-04-18 |
2023-10-26 |
Regenxbio Inc. |
Hybrid aav capsids
|
GB202206336D0
(en)
|
2022-04-29 |
2022-06-15 |
Univ Edinburgh |
Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
|
WO2023215807A1
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS
|
TW202400803A
(zh)
|
2022-05-03 |
2024-01-01 |
美商銳進科斯生物股份有限公司 |
載體化抗補體抗體與補體劑及其投與
|
WO2023214346A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023230409A1
(en)
*
|
2022-05-24 |
2023-11-30 |
Kate Therapeutics, Inc. |
Compositions for treating xlmtm
|
WO2023235791A1
(en)
|
2022-06-02 |
2023-12-07 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2023240158A2
(en)
*
|
2022-06-07 |
2023-12-14 |
Oregon Health & Science University |
Mutant adeno-associated virus (aav) capsids
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
WO2024006741A1
(en)
|
2022-06-28 |
2024-01-04 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2024003687A1
(en)
|
2022-06-28 |
2024-01-04 |
Pfizer Inc. |
Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024011112A1
(en)
|
2022-07-06 |
2024-01-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024038365A1
(en)
|
2022-08-16 |
2024-02-22 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
WO2024044725A2
(en)
|
2022-08-24 |
2024-02-29 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
WO2024042485A1
(en)
|
2022-08-25 |
2024-02-29 |
Takeda Pharmaceutical Company Limited |
Composition for use in the treatment of fabry disease
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
WO2024064863A2
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors
|
WO2024064856A1
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of cardiomyopathy with aav gene therapy vectors
|
WO2024073669A1
(en)
|
2022-09-30 |
2024-04-04 |
Regenxbio Inc. |
Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab
|
WO2024077089A2
(en)
*
|
2022-10-04 |
2024-04-11 |
Siren Biotechnology, Inc. |
Modified cpg dinucleotides for recombinant viral vector production
|
WO2024081746A2
(en)
|
2022-10-11 |
2024-04-18 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
WO2024105638A1
(en)
|
2022-11-18 |
2024-05-23 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of hunter syndrome
|